

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

**COMPLETION OF SUBSCRIPTION OF NEW SHARES
UNDER GENERAL MANDATE**

Reference is made to the announcements of Touyun Biotech Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 25 August 2026 and 31 August 2026 (the “**Announcements**”) in relation to the Subscription. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the conditions to the Agreement have been fulfilled and Completion took place on 7 September 2026. A total of 123,000,000 Subscription Shares, representing 4.38% of the issued share capital of the Company immediately before Completion and approximately 4.20% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares, have been successfully allotted and issued to the Subscriber at the Subscription Price of HK\$0.122 per Subscription Share.

The gross proceeds raised from the Subscription amounted to HK\$15,006,000, and the net proceeds, after deduction of all relevant expenses, amounted to approximately HK\$14,990,000. The net proceeds are intended to be fully utilised by 31 December 2026 and applied as follows:

1. HK\$7,000,000 for capital injection into Ronghe Shidai (Chongqing) New Material Technology Co., Ltd.*, an indirect non-wholly-owned subsidiary of the Group principally engaged in the research and development, manufacturing and sales of high thermal conductivity new materials, for the construction of a new production line for such high thermal conductivity new materials in order to satisfy existing and future market orders;
2. HK\$4,000,000 for repayment and settlement of the Group’s outstanding payables; and

3. HK\$3,990,000 for general working capital for daily operational expenses of the Group, including but not limited to staff costs and payroll, audit fees and other professional fees, and general office and operational expenses.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below is the shareholding structure of the Company immediately before and after the Completion:

	Immediately before Completion		Immediately after Completion	
	<i>Number of Shares</i>	<i>Approximate percentage of shareholding</i>	<i>Number of Shares</i>	<i>Approximate percentage of shareholding</i>
Mr. Wang Liang (<i>Note 1</i>)	617,500,000	22.01	617,500,000	21.08
Mr. Qin Fen	197,470,000	7.04	197,470,000	6.74
Ms. Qiao Yanfeng (<i>Note 2</i>)	150,000,000	5.35	150,000,000	5.12
Ms. Tian Yuze (<i>Note 3</i>)	145,805,135	5.20	145,805,135	4.98
The Subscriber	—	—	123,000,000	4.20
Other Shareholders	<u>1,695,177,014</u>	<u>60.40</u>	<u>1,695,177,014</u>	<u>57.88</u>
Total	<u>2,805,952,149</u>	<u>100</u>	<u>2,928,952,149</u>	<u>100</u>

Notes:

1. Mr. Wang Liang is the chairman and an executive Director of the Company.
2. Ms. Qiao Yanfeng (“**Ms. Qiao**”) is deemed to be interested in 150,000,000 shares through TY Technology Group Limited which is in turn owned as to 90% by Wise Tech Enterprises Incorporated (wholly-owned by Ms. Qiao) and 10% by Truthful Bright International Holding Limited (wholly-owned by Ms. Qiao). Ms. Qiao is Mr. Wang Liang’s mother.
3. Ms. Tian Yuze is a non-executive Director of the Company.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 7 September 2026

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Ms. Zhou Ruijuan (*Vice chairlady*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen

** For identification purposes only*